SAN DIEGO - Ainos, Inc. (NASDAQ:AIMD), a healthcare company with a focus on AI-driven diagnostics and therapeutics, announced today that it has been granted a patent in Taiwan for its antiviral formulation VELDONA®, which is aimed at treating and preventing coronavirus infections. The patent, titled "METHOD AND COMPOSITION OF TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION" and numbered TW202402785A, highlights a new therapeutic method using VELDONA® as a key component.
VELDONA® is an oral rapid-dissolving tablet designed for sublingual or buccal absorption, which Ainos claims enhances the immune system's function and reduces the risk of coronavirus infections. The company suggests that this technology improves drug bioavailability and patient compliance compared to traditional administration methods.
The company's research indicates that VELDONA® not only activates the immune system to fight various coronavirus strains but also has the potential to prevent new infections. Ainos also believes that the application of VELDONA® could extend to other viral diseases due to the immune-inducing properties of interferon, the primary ingredient in VELDONA®.
Dr. Albert Yu, Technical Director of Pharmaceuticals at Ainos and one of the primary inventors of the patent, expressed optimism about the patent's significance for global coronavirus mitigation efforts and the potential for VELDONA®'s clinical application worldwide.
Ainos, headquartered in San Diego, California, is involved in the development of human and animal oral therapeutics, orphan drugs, and telehealth-friendly point-of-care testing solutions. The company has emphasized its commitment to leveraging AI technology in healthcare through its product pipeline.
This announcement is based on a press release statement, and it marks a notable development for Ainos in its pursuit of advancing antiviral treatments. The company's stock is traded on NASDAQ under the tickers AIMD and AIMDW.
In other recent news, Ainos, Inc. has made significant advancements in its AI Nose technology, achieving a 79% accuracy rate in detecting volatile organic compounds (VOCs) in Japanese semiconductor factories. This development is a crucial step in enhancing safety and efficiency in the industrial sector. The company also plans to integrate this technology into robotics systems within smart factories.
In a strategic move, Ainos has secured exclusive licenses for 10 invention patents from Taiwan Carbon Nano Technology (TCNT), valued at approximately $5.4 million. This acquisition is expected to bolster the company's AI Nose and point-of-care testing technologies. Ainos has also extended its product development agreement with TCNT for an additional three months, allowing continued non-exclusive access to TCNT's patents.
However, Ainos faces a potential delisting from the Nasdaq due to its stock price falling below the required minimum bid price. The company has been given a grace period until January 13, 2025, to regain compliance. These are the recent developments in Ainos Inc.'s ongoing efforts.
InvestingPro Insights
As Ainos, Inc. (NASDAQ:AIMD) secures a new patent for its antiviral formulation in Taiwan, investors are closely watching the company's financial health and market position. According to InvestingPro, Ainos faces challenges with its cash flow and profitability. Specifically, Ainos is quickly burning through cash and has not been profitable over the last twelve months. These InvestingPro Tips highlight the importance for potential investors to consider the company's financial sustainability alongside its scientific advancements.
On the financial data front, Ainos's market capitalization stands at a modest 5.15 million USD, reflecting the size of the company in the competitive healthcare sector. The company's gross profit margin has been reported at a concerning -316.61% for the last twelve months as of Q2 2024, underlining struggles in maintaining profitability. Additionally, the stock price has experienced a significant decline over the past year, with a 1-year price total return of -79.02%. These metrics suggest that while Ainos may be making strides in product development, its financial performance remains under pressure.
Investors seeking more in-depth analysis can find additional InvestingPro Tips for Ainos, which provide further guidance on the company's valuation and industry position. With a total of seven tips available, these insights can offer a more comprehensive understanding of Ainos's investment potential and market dynamics.
For those interested in exploring the detailed financial outlook and strategic positioning of Ainos, visiting the dedicated page on InvestingPro could provide valuable perspective: https://www.investing.com/pro/AIMD
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.